Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication
In pregnant women with IBD, changes in liver enzyme levels reflect physiological gestational adaptations rather than pharmacologic effects. Although medication-specific interactions were detected, their clinical significance appears limited. Marked elevations in liver enzymes during pregnancy cannot routinely be attributed to IBD activity or medication and warrant urgent analysis.
Authors
- D G Bouwknegt (ORCID: https://orcid.org/0000-0002-6208-2967)
- Geke Dijkstra (ORCID: https://orcid.org/0000-0001-5622-4730)
- Marijn C. Visschedijk (ORCID: https://orcid.org/0000-0001-7277-7677)
- Hylke C. Donker (ORCID: https://orcid.org/0000-0001-5648-9552)
- Willemijn A. van Dop (ORCID: https://orcid.org/0000-0002-4653-6594)
- Jelmer R. Prins (ORCID: https://orcid.org/0000-0002-3984-2163)
- Tjebbe Tauber
- Bram van Es (ORCID: https://orcid.org/0000-0003-4667-1304)
- C. Janneke van der Woude
- On behalf of the Dutch Initiative on Crohn and Colitis (ICC)
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- University Medical Center (US)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- MEDRx (Japan) (JP)
Publication Details
- Journal
- Scandinavian Journal of Gastroenterology
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1080/00365521.2025.2606769
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- ZonMw
- United European Gastroenterology
- DSM
- Cilag